Diaminopropanol tetraacetic acid
- Generic Name
- Diaminopropanol tetraacetic acid
- Drug Type
- Small Molecule
- Chemical Formula
- C11H18N2O9
- CAS Number
- 3148-72-9
- Unique Ingredient Identifier
- 949B9ZMO7M
- Background
Diaminohydroxypropanetetraacetic acid has been investigated for the treatment of Vascular Disease, Coronary Disease, Myocardial Ischemia, Coronary Restenosis, and Coronary Artery Disease, among others.
Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration
- Conditions
- Percutaneous Coronary InterventionDual Antiplatelet TherapyCoronary Artery Disease
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 16000
- Registration Number
- NCT03338335
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Duk-Woo Park, MD
- Target Recruit Count
- 235
- Registration Number
- NCT03284827
- Locations
- ðŸ‡ðŸ‡°
Queen Mary Hospital, Hong Kong, Hong Kong
🇰🇷Bundang CHA Hospital, Seongnam, Korea, Republic of
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
- Conditions
- Atrial FibrillationAtrial AppendageHemorrhage
- Interventions
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 105
- Registration Number
- NCT03273322
- Locations
- 🇫🇷
Institut de Cardiologie - Hôpital Pitié-Salpêtrière, Paris, France
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Abbott Medical Devices
- Target Recruit Count
- 2047
- Registration Number
- NCT03218787
- Locations
- 🇺🇸
MedStar Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Baystate Medical Center, Springfield, Massachusetts, United States
The IDEAL-PCI Extended Registry
- Conditions
- Coronary ArteriosclerosesPlatelet Dysfunction Due to Drugs
- Interventions
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Kaiser Franz Josef Hospital
- Registration Number
- NCT02974777
- Locations
- 🇦🇹
Kaiser Franz Josef Hospital, Vienna, Austria
Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PAD
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 300
- Registration Number
- NCT02798913
- Locations
- 🇮🇹
Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Kyoto University, Graduate School of Medicine
- Target Recruit Count
- 3045
- Registration Number
- NCT02619760
- Locations
- 🇯🇵
Division of Cardiology, Kyoto University Hospital, Kyoto, Japan
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
- Conditions
- Non-ST Segment Elevation Myocardial InfarctionStable AnginaUnstable Angina
- Interventions
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 2173
- Registration Number
- NCT02601157
- Locations
- 🇰🇷
Gwangju Christian Hospital, Gwangju, Korea, Republic of
🇰🇷Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷Ewha Womans University Medical Center Mokdong Hospital, Seoul, Korea, Republic of
COBRA SHIELD OCT Study
- Conditions
- Stable Angina
- Interventions
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- CeloNova BioSciences, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02224235
- Locations
- 🇫🇮
Heart Center, Turku University Hospital, Turku, Finland
🇫🇮Satakunta Central Hospital, Pori, Finland
DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents(EES) Versus Biolimus A9-eluting Stents(BES)
- Conditions
- Ischemic Heart Disease
- Interventions
- Device: PCI with BES under angio-guide or OCT guideDevice: PCI with EES under angio-guide or OCT guideDevice: OCT-guided PCI with EES or BESDevice: Angio-guided PCI with EES or BES
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 776
- Registration Number
- NCT01752894
- Locations
- 🇰🇷
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.